{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T14:01:03Z","timestamp":1790863263499,"version":"4.1.0"},"reference-count":21,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,16]],"date-time":"2025-08-16T00:00:00Z","timestamp":1755302400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.clml.2025.08.014","type":"journal-article","created":{"date-parts":[[2025,8,18]],"date-time":"2025-08-18T08:42:31Z","timestamp":1755506551000},"page":"e1121-e1126","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Predicators and Outcomes of Cytomegalovirus Reactivation in Chimeric Antigen Receptor T-Cell Therapy: A Systematic Review"],"prefix":"10.1016","volume":"25","author":[{"given":"Muhammad Atif","family":"Khan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faiza Humayun","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abat","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aneela","family":"Majeed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1068-2493","authenticated-orcid":false,"given":"Chelsea","family":"Gorsline","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nausheen","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.clml.2025.08.014_bib0001","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1056\/NEJMoa1709919","article-title":"Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia","volume":"378","author":"Park","year":"2018","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.clml.2025.08.014_bib0002","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.clml.2025.08.014_bib0003","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene Vicleucel in relapsed and refractory multiple myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"N Engl J Med"},{"issue":"26","key":"10.1016\/j.clml.2025.08.014_bib0004","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.clml.2025.08.014_bib0005","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1038\/s41408-020-00346-7","article-title":"Infection during the first year in patients treated with CD19 CAR T cells for diffuse large B cell lymphoma","volume":"10","author":"Wudhikarn","year":"2020","journal-title":"Blood Cancer J"},{"issue":"9","key":"10.1016\/j.clml.2025.08.014_bib0006","doi-asserted-by":"crossref","first-page":"2667","DOI":"10.1038\/s41591-024-03084-6","article-title":"A systematic review and meta-analysis of nonrelapse mortality after CAR T cell therapy","volume":"30","author":"Cordas Dos Santos","year":"2024","journal-title":"Nat Med"},{"issue":"19","key":"10.1016\/j.clml.2025.08.014_bib0007","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1182\/blood.2019000956","article-title":"How I treat CMV reactivation after allogeneic hematopoietic stem cell transplantation","volume":"135","author":"Einsele","year":"2020","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.clml.2025.08.014_bib0008","doi-asserted-by":"crossref","first-page":"615","DOI":"10.3324\/haematol.2022.281719","article-title":"Cytomegalovirus reactivation after CD19 CAR T-cell therapy is clinically significant","volume":"108","author":"Chen","year":"2023","journal-title":"Haematologica"},{"issue":"6","key":"10.1016\/j.clml.2025.08.014_bib0009","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1038\/s41571-023-00754-1","article-title":"Long-term outcomes following CAR T cell therapy: what we know so far","volume":"20","author":"Cappell","year":"2023","journal-title":"Nat Rev Clin Oncol"},{"issue":"4","key":"10.1016\/j.clml.2025.08.014_bib0010","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1093\/cid\/ciad708","article-title":"Cytomegalovirus (CMV) reactivation and CMV-specific cell-mediated immunity after chimeric antigen receptor T-cell therapy","volume":"78","author":"Kampouri","year":"2024","journal-title":"Clin Infect Dis"},{"issue":"8","key":"10.1016\/j.clml.2025.08.014_bib0011","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofae422","article-title":"Cytomegaloviral infections in recipients of chimeric antigen receptor T-cell therapy: an observational study with focus on oncologic outcomes","volume":"11","author":"Khawaja","year":"2024","journal-title":"Open Forum Infect Dis"},{"issue":"14","key":"10.1016\/j.clml.2025.08.014_bib0012","doi-asserted-by":"crossref","first-page":"3813","DOI":"10.1182\/bloodadvances.2024012922","article-title":"Incidence and outcomes of cytomegalovirus reactivation after chimeric antigen receptor T-cell therapy","volume":"8","author":"Lin","year":"2024","journal-title":"Blood Adv"},{"issue":"1","key":"10.1016\/j.clml.2025.08.014_bib0013","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0317383","article-title":"Taming the transplant troll: exploring racial and ethnic disparities in cytomegalovirus infection among kidney transplant patients","volume":"20","author":"Cabanilla","year":"2025","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.clml.2025.08.014_bib0014","doi-asserted-by":"crossref","first-page":"328.e1","DOI":"10.1016\/j.jtct.2024.01.055","article-title":"Disparities in Cytomegalovirus infection rates by race and ethnicity among pediatric allogeneic hematopoietic cell transplantation recipients at a single center","volume":"30","author":"Boge","year":"2024","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.clml.2025.08.014_bib0015","unstructured":"Surveillance epidemiology, and end results (SEER) program. NCI's Division of Cancer Control and Population Sciences. https:\/\/seer.cancer.gov\/, 2020."},{"key":"10.1016\/j.clml.2025.08.014_bib0016","unstructured":"FDA approves CAR-T cell therapy to treat adults with certain types of large B-cell lymphoma. 2017."},{"key":"10.1016\/j.clml.2025.08.014_bib0017","doi-asserted-by":"crossref","first-page":"102039","DOI":"10.1016\/j.trim.2024.102039","article-title":"Predictors of cytomegalovirus reactivation after allogeneic hematopoietic cell transplantation: insights from a real-world experience","volume":"84","author":"McGuirk","year":"2024","journal-title":"Transpl Immunol"},{"issue":"10","key":"10.1016\/j.clml.2025.08.014_bib0018","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1038\/s41408-021-00563-8","article-title":"Viral infection\/reactivation during long-term follow-up in multiple myeloma patients with anti-BCMA CAR therapy","volume":"11","author":"Wang","year":"2021","journal-title":"Blood Cancer J"},{"issue":"1","key":"10.1016\/j.clml.2025.08.014_bib0019","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.hoc.2010.11.011","article-title":"Cytomegalovirus in hematopoietic stem cell transplant recipients","volume":"25","author":"Ljungman","year":"2011","journal-title":"Hematol Oncol Clin North Am"},{"issue":"8","key":"10.1016\/j.clml.2025.08.014_bib0020","doi-asserted-by":"crossref","first-page":"521.e1","DOI":"10.1016\/j.jtct.2023.04.023","article-title":"Cytomegalovirus infection post-allogeneic stem cell transplantation: experience from a country with high seropositivity","volume":"29","author":"Iftikhar","year":"2023","journal-title":"Transplant Cell Ther"},{"issue":"10","key":"10.1016\/j.clml.2025.08.014_bib0021","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/j.jtct.2024.07.018","article-title":"Best practice considerations by the American Society of Transplant and Cellular Therapy: infection prevention and management after chimeric antigen receptor T cell Therapy for hematological malignancies","volume":"30","author":"Shahid","year":"2024","journal-title":"Transplant Cell Ther"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265025002976?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265025002976?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,22]],"date-time":"2025-11-22T01:09:56Z","timestamp":1763773796000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265025002976"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":21,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["S2152265025002976"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2025.08.014","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Predicators and Outcomes of Cytomegalovirus Reactivation in Chimeric Antigen Receptor T-Cell Therapy: A Systematic Review","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2025.08.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}